Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9EYI

Cryo-EM structure of SAVED-Lon protease CCaCalpL filament bound to A4p

Summary for 9EYI
Entry DOI10.2210/pdb9eyi/pdb
EMDB information50054
DescriptorSMODS-associated and fused to various effectors domain-containing protein, A4p (5'-R(*AP*AP*AP*AP)-3') (2 entities in total)
Functional Keywordslon protease, saved domain, crispr, hydrolase
Biological sourceCandidatus Cloacimonas acidaminovorans
More
Total number of polymer chains5
Total formula weight192586.21
Authors
Tamulaitiene, G.,Sasnauskas, G.,Smalakyte, D.,Tamulaitis, G. (deposition date: 2024-04-09, release date: 2024-10-02, Last modification date: 2024-12-18)
Primary citationSmalakyte, D.,Ruksenaite, A.,Sasnauskas, G.,Tamulaitiene, G.,Tamulaitis, G.
Filament formation activates protease and ring nuclease activities of CRISPR Lon-SAVED.
Mol.Cell, 84:4239-4255.e8, 2024
Cited by
PubMed Abstract: To combat phage infection, type III CRISPR-Cas systems utilize cyclic oligoadenylates (cA) signaling to activate various auxiliary effectors, including the CRISPR-associated Lon-SAVED protease CalpL, which forms a tripartite effector system together with an anti-σ factor, CalpT, and an ECF-like σ factor, CalpS. Here, we report the characterization of the Candidatus Cloacimonas acidaminovorans CalpL-CalpT-CalpS. We demonstrate that cA binding triggers CalpL filament formation and activates it to cleave CalpT within the CalpT-CalpS dimer. This cleavage exposes the CalpT C-degron, which targets it for further degradation by cellular proteases. Consequently, CalpS is released to bind to RNA polymerase, causing growth arrest in E. coli. Furthermore, the CalpL-CalpT-CalpS system is regulated by the SAVED domain of CalpL, which is a ring nuclease that cleaves cA in a sequential three-step mechanism. These findings provide key mechanistic details for the activation, proteolytic events, and regulation of the signaling cascade in the type III CRISPR-Cas immunity.
PubMed: 39362215
DOI: 10.1016/j.molcel.2024.09.002
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (2.75 Å)
Structure validation

234136

PDB entries from 2025-04-02

PDB statisticsPDBj update infoContact PDBjnumon